Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
KeyBioscience AG · Osteoarthritis in the Knee · Obesity
Phase 2
Recruiting
600
2025-02
Industry sponsor intelligence
KeyBioscience AGClinical Pipeline.
Lead-sponsor view of KeyBioscience AG's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 1
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 600
Pipeline overview
Programs by phase and activity.
Velocity
KeyBioscience AG trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Calcitonin → | 1 | 0 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All KeyBioscience AG studies.
This page groups studies where KeyBioscience AG is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates